ChemBriefPfizer Beats Earnings Estimates, Targets $2.5 Billion in Additional Cost Cuts
Pfizer reported better-than-expected Q2 earnings driven by Eliquis sales and announced $2.5 billion in cost cuts through 2029. The company aims to offset declining COVID revenue while expanding into t
reuters · 2026-08-04 03:52